Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study

Sæmundur Rögnvaldsson; Elias Eythorsson; Sigrun Thorsteinsdottir; Brynjar Vidarsson; Páll Torfi Önundarson; Bjarni Agnar Agnarsson; Margret Sigurdardottir; Ingunn Thorsteinsdóttir; Ísleifur Ólafsson; Hrafnhildur L. Runólfsdóttir; Dadi Helgason; Arna Rut Emilsdóttir; Arnar Snær Ágústsson; Aron Hjalti Björnsson; Gudrún Kristjánsdóttir; Asdis Rosa Thordardottir; Olafur Skuli Indridason; Ásbjörn Jónsson; Gauti Kjartan Gislason; Andri Olafsson; Hlíf Steingrímsdóttir; Petros Kampanis; Malin Hultcrantz; Brian G.M. Durie; Stephen Harding; Ola Landgren; Runolfur Palsson; Thorvarður Jon Love; Sigurdur Yngvi Kristinsson

doi:10.1038/s41408-021-00580-7

Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study

Sæmundur Rögnvaldsson, Elias Eythorsson, Sigrun Thorsteinsdottir, Brynjar Vidarsson, Páll Torfi Önundarson, Bjarni Agnar Agnarsson, Margret Sigurdardottir, Ingunn Thorsteinsdóttir, Ísleifur Ólafsson, Hrafnhildur L. Runólfsdóttir, Dadi Helgason, Arna Rut Emilsdóttir, Arnar Snær Ágústsson, Aron Hjalti Björnsson, Gudrún Kristjánsdóttir, Asdis Rosa Thordardottir, Olafur Skuli Indridason, Ásbjörn Jónsson, Gauti Kjartan Gislason, Andri OlafssonHlíf Steingrímsdóttir, Petros Kampanis, Malin Hultcrantz, Brian G.M. Durie, Stephen Harding, Ola Landgren, Runolfur Palsson, Thorvarður Jon Love, Sigurdur Yngvi Kristinsson

University of Iceland

Research output: Contribution to journal › Article › peer-review

Abstract

Multiple myeloma (MM) patients have increased risk of severe coronavirus disease 2019 (COVID-19) when infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Monoclonal gammopathy of undetermined significance (MGUS), the precursor of MM has been associated with immune dysfunction which may lead to severe COVID-19. No systematic data have been published on COVID-19 in individuals with MGUS. We conducted a large population-based cohort study evaluating the risk of SARS-CoV-2 infection and severe COVID-19 among individuals with MGUS. We included 75,422 Icelanders born before 1976, who had been screened for MGUS in the Iceland Screens Treats or Prevents Multiple Myeloma study (iStopMM). Data on SARS-CoV-2 testing and COVID-19 severity were acquired from the Icelandic COVID-19 Study Group. Using a test-negative study design, we included 32,047 iStopMM participants who had been tested for SARS-CoV-2, of whom 1754 had MGUS. Among these participants, 1100 participants, tested positive, 65 of whom had MGUS. Severe COVID-19 developed in 230 participants, including 16 with MGUS. MGUS was not associated with SARS-CoV-2 infection (Odds ratio (OR): 1.05; 95% confidence interval (CI): 0.81–1.36; p = 0.72) or severe COVID-19 (OR: 0.99; 95%CI: 0.52–1.91; p = 0.99). These findings indicate that MGUS does not affect the susceptibility to SARS-CoV-2 or the severity of COVID-19.

Original language	English
Article number	191
Pages (from-to)	191
Journal	Blood Cancer Journal
Volume	11
Issue number	12
DOIs	https://doi.org/10.1038/s41408-021-00580-7
Publication status	Published - 1 Dec 2021

Bibliographical note

The iStopMM study is funded by the Black Swan Research Initiative by the International Myeloma Foundation, the European Research Council, and the Icelandic Center for Research. Screening tests were performed by The Binding Site Ltd, Birmingham, UK. Additional funding for the iStopMM study is provided by the University of Iceland, Landspítali—The National University Hospital of Iceland, and the Icelandic Cancer Society. The iStopMM study is made possible the nurses, data scientists, and other staff of the study as well as by the hundreds of nurses and laboratory technicians who had collected blood samples for the study. Most importantly, our gratitude goes to the thousands of Icelanders who have generously provided their informed consent for the study, answered questionnaires, provided blood samples, and undergone diagnostic testing and follow-up. Publisher Copyright: © 2021, The Author(s).

Other keywords

Adult
Aged
COVID-19/epidemiology
Cohort Studies
Female
Humans
Iceland/epidemiology
Male
Middle Aged
Monoclonal Gammopathy of Undetermined Significance/epidemiology
Risk Factors
SARS-CoV-2

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41408-021-00580-7

MGUS screening RCT: Screening for monoclonal gammopathy of undetermined significance: A population-based randomized clinical trial
Kristinsson, S. Y. (PI)
1/02/17 → 31/01/22
Project: Research
MGUS screening RCT: Screening for monoclonal gammopathy of undetermined significance: A population-based randomized clinical trial
Kristinsson, S. Y. (PI)
1/02/17 → 31/01/22
University of Iceland
Project: Research

Cite this

Rögnvaldsson, S., Eythorsson, E., Thorsteinsdottir, S., Vidarsson, B., Önundarson, P. T., Agnarsson, B. A., Sigurdardottir, M., Thorsteinsdóttir, I., Ólafsson, Í., Runólfsdóttir, H. L., Helgason, D., Emilsdóttir, A. R., Ágústsson, A. S., Björnsson, A. H., Kristjánsdóttir, G., Thordardottir, A. R., Indridason, O. S., Jónsson, Á., Gislason, G. K., ... Kristinsson, S. Y. (2021). Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study. Blood Cancer Journal, 11(12), 191. Article 191. https://doi.org/10.1038/s41408-021-00580-7

@article{a72118a7d1154aeeb6a0d6957fb362bc,

title = "Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study",

abstract = "Multiple myeloma (MM) patients have increased risk of severe coronavirus disease 2019 (COVID-19) when infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Monoclonal gammopathy of undetermined significance (MGUS), the precursor of MM has been associated with immune dysfunction which may lead to severe COVID-19. No systematic data have been published on COVID-19 in individuals with MGUS. We conducted a large population-based cohort study evaluating the risk of SARS-CoV-2 infection and severe COVID-19 among individuals with MGUS. We included 75,422 Icelanders born before 1976, who had been screened for MGUS in the Iceland Screens Treats or Prevents Multiple Myeloma study (iStopMM). Data on SARS-CoV-2 testing and COVID-19 severity were acquired from the Icelandic COVID-19 Study Group. Using a test-negative study design, we included 32,047 iStopMM participants who had been tested for SARS-CoV-2, of whom 1754 had MGUS. Among these participants, 1100 participants, tested positive, 65 of whom had MGUS. Severe COVID-19 developed in 230 participants, including 16 with MGUS. MGUS was not associated with SARS-CoV-2 infection (Odds ratio (OR): 1.05; 95\% confidence interval (CI): 0.81–1.36; p = 0.72) or severe COVID-19 (OR: 0.99; 95\%CI: 0.52–1.91; p = 0.99). These findings indicate that MGUS does not affect the susceptibility to SARS-CoV-2 or the severity of COVID-19.",

keywords = "Adult, Aged, COVID-19/epidemiology, Cohort Studies, Female, Humans, Iceland/epidemiology, Male, Middle Aged, Monoclonal Gammopathy of Undetermined Significance/epidemiology, Risk Factors, SARS-CoV-2",

author = "S{\ae}mundur R{\"o}gnvaldsson and Elias Eythorsson and Sigrun Thorsteinsdottir and Brynjar Vidarsson and {\"O}nundarson, \{P{\'a}ll Torfi\} and Agnarsson, \{Bjarni Agnar\} and Margret Sigurdardottir and Ingunn Thorsteinsd{\'o}ttir and {\'I}sleifur {\'O}lafsson and Run{\'o}lfsd{\'o}ttir, \{Hrafnhildur L.\} and Dadi Helgason and Emilsd{\'o}ttir, \{Arna Rut\} and {\'A}g{\'u}stsson, \{Arnar Sn{\ae}r\} and Bj{\"o}rnsson, \{Aron Hjalti\} and Gudr{\'u}n Kristj{\'a}nsd{\'o}ttir and Thordardottir, \{Asdis Rosa\} and Indridason, \{Olafur Skuli\} and {\'A}sbj{\"o}rn J{\'o}nsson and Gislason, \{Gauti Kjartan\} and Andri Olafsson and Hl{\'i}f Steingr{\'i}msd{\'o}ttir and Petros Kampanis and Malin Hultcrantz and Durie, \{Brian G.M.\} and Stephen Harding and Ola Landgren and Runolfur Palsson and Love, \{Thorvar{\dh}ur Jon\} and Kristinsson, \{Sigurdur Yngvi\}",

note = "The iStopMM study is funded by the Black Swan Research Initiative by the International Myeloma Foundation, the European Research Council, and the Icelandic Center for Research. Screening tests were performed by The Binding Site Ltd, Birmingham, UK. Additional funding for the iStopMM study is provided by the University of Iceland, Landsp{\'i}tali—The National University Hospital of Iceland, and the Icelandic Cancer Society. The iStopMM study is made possible the nurses, data scientists, and other staff of the study as well as by the hundreds of nurses and laboratory technicians who had collected blood samples for the study. Most importantly, our gratitude goes to the thousands of Icelanders who have generously provided their informed consent for the study, answered questionnaires, provided blood samples, and undergone diagnostic testing and follow-up. Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

day = "1",

doi = "10.1038/s41408-021-00580-7",

language = "English",

volume = "11",

pages = "191",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "12",

}

Rögnvaldsson, S, Eythorsson, E, Thorsteinsdottir, S, Vidarsson, B , Önundarson, PT, Agnarsson, BA, Sigurdardottir, M , Thorsteinsdóttir, I , Ólafsson, Í , Runólfsdóttir, HL, Helgason, D, Emilsdóttir, AR, Ágústsson, AS, Björnsson, AH, Kristjánsdóttir, G, Thordardottir, AR, Indridason, OS, Jónsson, Á, Gislason, GK, Olafsson, A, Steingrímsdóttir, H, Kampanis, P, Hultcrantz, M, Durie, BGM, Harding, S, Landgren, O, Palsson, R , Love, TJ & Kristinsson, SY 2021, 'Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study', Blood Cancer Journal, vol. 11, no. 12, 191, pp. 191. https://doi.org/10.1038/s41408-021-00580-7

TY - JOUR

T1 - Monoclonal gammopathy of undetermined significance and COVID-19

T2 - a population-based cohort study

AU - Rögnvaldsson, Sæmundur

AU - Eythorsson, Elias

AU - Thorsteinsdottir, Sigrun

AU - Vidarsson, Brynjar

AU - Önundarson, Páll Torfi

AU - Agnarsson, Bjarni Agnar

AU - Sigurdardottir, Margret

AU - Thorsteinsdóttir, Ingunn

AU - Ólafsson, Ísleifur

AU - Runólfsdóttir, Hrafnhildur L.

AU - Helgason, Dadi

AU - Emilsdóttir, Arna Rut

AU - Ágústsson, Arnar Snær

AU - Björnsson, Aron Hjalti

AU - Kristjánsdóttir, Gudrún

AU - Thordardottir, Asdis Rosa

AU - Indridason, Olafur Skuli

AU - Jónsson, Ásbjörn

AU - Gislason, Gauti Kjartan

AU - Olafsson, Andri

AU - Steingrímsdóttir, Hlíf

AU - Kampanis, Petros

AU - Hultcrantz, Malin

AU - Durie, Brian G.M.

AU - Harding, Stephen

AU - Landgren, Ola

AU - Palsson, Runolfur

AU - Love, Thorvarður Jon

AU - Kristinsson, Sigurdur Yngvi

N1 - The iStopMM study is funded by the Black Swan Research Initiative by the International Myeloma Foundation, the European Research Council, and the Icelandic Center for Research. Screening tests were performed by The Binding Site Ltd, Birmingham, UK. Additional funding for the iStopMM study is provided by the University of Iceland, Landspítali—The National University Hospital of Iceland, and the Icelandic Cancer Society. The iStopMM study is made possible the nurses, data scientists, and other staff of the study as well as by the hundreds of nurses and laboratory technicians who had collected blood samples for the study. Most importantly, our gratitude goes to the thousands of Icelanders who have generously provided their informed consent for the study, answered questionnaires, provided blood samples, and undergone diagnostic testing and follow-up. Publisher Copyright: © 2021, The Author(s).

PY - 2021/12/1

Y1 - 2021/12/1

N2 - Multiple myeloma (MM) patients have increased risk of severe coronavirus disease 2019 (COVID-19) when infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Monoclonal gammopathy of undetermined significance (MGUS), the precursor of MM has been associated with immune dysfunction which may lead to severe COVID-19. No systematic data have been published on COVID-19 in individuals with MGUS. We conducted a large population-based cohort study evaluating the risk of SARS-CoV-2 infection and severe COVID-19 among individuals with MGUS. We included 75,422 Icelanders born before 1976, who had been screened for MGUS in the Iceland Screens Treats or Prevents Multiple Myeloma study (iStopMM). Data on SARS-CoV-2 testing and COVID-19 severity were acquired from the Icelandic COVID-19 Study Group. Using a test-negative study design, we included 32,047 iStopMM participants who had been tested for SARS-CoV-2, of whom 1754 had MGUS. Among these participants, 1100 participants, tested positive, 65 of whom had MGUS. Severe COVID-19 developed in 230 participants, including 16 with MGUS. MGUS was not associated with SARS-CoV-2 infection (Odds ratio (OR): 1.05; 95% confidence interval (CI): 0.81–1.36; p = 0.72) or severe COVID-19 (OR: 0.99; 95%CI: 0.52–1.91; p = 0.99). These findings indicate that MGUS does not affect the susceptibility to SARS-CoV-2 or the severity of COVID-19.

AB - Multiple myeloma (MM) patients have increased risk of severe coronavirus disease 2019 (COVID-19) when infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Monoclonal gammopathy of undetermined significance (MGUS), the precursor of MM has been associated with immune dysfunction which may lead to severe COVID-19. No systematic data have been published on COVID-19 in individuals with MGUS. We conducted a large population-based cohort study evaluating the risk of SARS-CoV-2 infection and severe COVID-19 among individuals with MGUS. We included 75,422 Icelanders born before 1976, who had been screened for MGUS in the Iceland Screens Treats or Prevents Multiple Myeloma study (iStopMM). Data on SARS-CoV-2 testing and COVID-19 severity were acquired from the Icelandic COVID-19 Study Group. Using a test-negative study design, we included 32,047 iStopMM participants who had been tested for SARS-CoV-2, of whom 1754 had MGUS. Among these participants, 1100 participants, tested positive, 65 of whom had MGUS. Severe COVID-19 developed in 230 participants, including 16 with MGUS. MGUS was not associated with SARS-CoV-2 infection (Odds ratio (OR): 1.05; 95% confidence interval (CI): 0.81–1.36; p = 0.72) or severe COVID-19 (OR: 0.99; 95%CI: 0.52–1.91; p = 0.99). These findings indicate that MGUS does not affect the susceptibility to SARS-CoV-2 or the severity of COVID-19.

KW - Adult

KW - Aged

KW - COVID-19/epidemiology

KW - Cohort Studies

KW - Female

KW - Humans

KW - Iceland/epidemiology

KW - Male

KW - Middle Aged

KW - Monoclonal Gammopathy of Undetermined Significance/epidemiology

KW - Risk Factors

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85120645077&partnerID=8YFLogxK

U2 - 10.1038/s41408-021-00580-7

DO - 10.1038/s41408-021-00580-7

M3 - Article

C2 - 34853309

SN - 2044-5385

VL - 11

SP - 191

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 12

M1 - 191

ER -

Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study

Abstract

Bibliographical note

Other keywords

UN SDGs

Access to Document

Fingerprint

Projects

MGUS screening RCT: Screening for monoclonal gammopathy of undetermined significance: A population-based randomized clinical trial

MGUS screening RCT: Screening for monoclonal gammopathy of undetermined significance: A population-based randomized clinical trial

Cite this